BioAtla, Inc. (BCAB)
| Market Cap | 86.05M |
| Revenue (ttm) | 250,000 |
| Net Income (ttm) | -100.96M |
| Shares Out | 37.41M |
| EPS (ttm) | -2.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 148,368 |
| Open | 2.30 |
| Previous Close | 2.39 |
| Day's Range | 2.27 - 2.34 |
| 52-Week Range | 2.01 - 51.83 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 33.15 (+1,341.3%) |
| Earnings Date | May 4, 2022 |
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen...
Financial Performance
In 2021, BioAtla's revenue was $250,000, a decrease of -41.72% compared to the previous year's $429,000. Losses were -$95.40 million, 166.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is 33.15, which is an increase of 1,341.30% from the latest price.
News
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and o...
BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftam...
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...
BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today annou...
BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update
SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...
BioAtla Announces Private Placement of 2.7 Million Shares
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeut...
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutic...
BioAtla to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...
BioAtla Announces Pricing of Initial Public Offering
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...